Induction of specific T-cell responses in HIV infection

AIDS

Volumn 12, Issue 2, 1998, Pages 157-166

  Leandersson, Ann Charlotte ^a,d   Bratt, Göran ^b   Hinkula, Jorma ^a   Gilljam, Gustav ^a   Cochaux, Pascale ^c   Samson, Michel ^c   Sandström, Eric ^b   Wahren, Britta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Antiviral treatment; HIV 1; T cell response; Therapeutic vaccination

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; RECOMBINANT PROTEIN; ZIDOVUDINE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE CLONE; LYMPHOCYTE COUNT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

AIDS VACCINES; ANTI-HIV AGENTS; APOPTOSIS; CD4 LYMPHOCYTE COUNT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, CCR5; T-LYMPHOCYTES; VACCINATION; VACCINES, SYNTHETIC; VIRAL LOAD; ZIDOVUDINE;

EID: 0032556931     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199802000-00005     Document Type: Article

References (47)

1. Wahren B, Morfeldt-Mansson L, Biberfeld G, et al.: Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol 1987, 61:2017-2023.
2. Tacket CO, Baqar S, Munoz C, Murphy JR: Lymphoproliferative responses to mitogens and HIV-1 envelope glycoprotein among volunteers vaccinated with recombinant gp160. AIDS Res Hum Retroviruses 1990, 6:535-542.
3. Shearer GM, Clerici M: Early T-helper cell defects in HIV infection. AIDS 1991, 5:245-253.
4. Clerici M, Shearer GM: The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994, 15:575-581.
5. Clerici M: Cell-mediated immunity in HIV infection. AIDS 1993, 7 (suppl 1):S135-S140.
6. Wahren B, Bratt G, Persson C, et al.: Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994, 7:220-229.
7. Redfield RR, Birx DL, Ketter N, et al.: A Phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991, 324:1677-1684.
8. Levine AM, Groshen S, Allen J, et al.: Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:351-364.
9. Stanley S, Ostrowski MA, Justement JS, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334:1222-1230.
10. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
11. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
12. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
13. Chirmule N, Kalyanaraman VS, Oyaizu N, Slade HB, Pahwa S: Inhibition of functional properties of tetanus antigen-specific T-cell clones by envelope glycoprotein gp120 of human immunodeficiency virus. Blood 1990, 75:152-159.
14. Oyaizu N, Chirmule N, Kalyanaraman VS, et al.: Human immunodeficiency virus type 1 envelope glycoprotein gp120 produces immune defects in CD4+ T lymphocytes by inhibiting interleukin 2 mRNA. Proc Natl Acad Sci USA 1990, 87:2379-2383 [Erratum Proc Natl Acad Sci USA 1990, 87:4022].
15. Kundu SK, Katzenstein D, Moses LE, Merigan TC: Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proc Natl Acad Sci USA 1992, 89:11204-11208.
16. Clerici M, Yarchoan R, Blatt S, et al.: Effect of a recombinant CD4-IgG on in vitro T helper cell function: data from a Phase I/II study of patients with AIDS. J Infect Dis 1993, 168:1012-1016.
17. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M: Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996, 35:3362-3367.
18. Deng H, Liu R, Ellmeier W, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
19. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
20. Samson M, Libert F, Doranz BJ, et al.: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
21. Eugen-Olsen J, Iversen AKN, Garred P, et al.: Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997, 11:305-310.
22. Huang YX, Paxton WA, Wolinsky SM, et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 1996, 2:1240-1243.
23. Bratt G, Leandersson L, Eriksson LE, et al.: Four years of Vaxsyn HIV-1 in asymptomatic HIV-positive individuals. XI International Conference on AIDS. Vancouver, July 1996 [abstract We.B. 3374].
24. Hodara VL, Jeddi-Tehrani M, Grunewald J, et al.: HIV infection leads to differential expression of T-cell receptor Vβ genes in CD4+and CD8+ T cells. AIDS 1993, 7:633-638.
25. Clerici M, Stocks NI, Zajac RA, et al.: Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989, 84:1892-1899.
26. Keefer MC, Bonnez W, Roberts NJ, Dolin R, Reichman RC: Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J Infect Dis 1991, 163:448-453.
27. Gorse GJ, Belshe RB, Newman FK, Frey SE: Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gp160. Vaccine 1992, 10:383-388.
28. Redfield RR, Birx DL: HIV-specific vaccine therapy: concepts, status, and future directions. AIDS Res Hum Retroviruses 1992, 8:1051-1058.
29. Clerici M, Tacket CO, Via CS, et al.: Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur J Immunol 1991, 21:1345-1349.
30. Birx DL, Davis C, Ruiz N, et al.: Results of a Phase II double-blinded, multicenter, placebo controlled HIV therapeutic vaccine trial. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA275].
31. Tsoukas CM, Raboud J, Schlech W, et al.: Active immunization of patients with HIV infection: a controlled study of the effect of Vaxsyn on progression of immune deficiency. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA274].
32. Eron JJ, Ashby MA, Giordano MF, et al.: Randomized trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996, 348:1547-1551.
33. Cocchi F, Devico AL, Garzinodemo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811-1815.
34. McKenzie SW, Dallalio G, North M, Frame P, Means Jr RT: Serum chemokine levels in patients with non-progressing HIV infection. AIDS 1996, 10:F29-F33.
35. Clerici M, Balotta C, Trabattoni D, et al.: Chemokine production in HIV-seropositive long-term asymptomatic individuals [letter]. AIDS 1996, 10:1432-1433.
36. Chen Y, Gupta P: CD8+ T-cell-mediated suppression of HIV-1 infection may not be due to chemokines RANTES, MIP-1α and MIP-1β [letter]. AIDS 1996, 10:1434-1435.
37. Zanussi S, D'Andrea M, Simonelli C, Tirelli U, De Paoli P: Serum levels of RANTES and MIP-1α in HIV-positive long-term survivors and progressor patients [letter]. AIDS 1996, 10:1431-1432.
38. Bratt G, Sandström E, Albert J, Samson M, Wahren B: The influence of MT-2 tropism on the prognostic implications of the Δ32 deletion in the CCR-5 gene. AIDS 1997, 11:1415-1419.
39. Woods TC, Roberts BD, Butera ST, Folks TM: Loss of inducible virus in CD45RA naive cells after human immunodeficiency virus-1 entry accounts for preferential viral replication in CD45RO memory cells. Blood 1997, 89:1635-1641.
40. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, Fauci AS: Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci USA 1990, 87:6058-6062.
41. Cayota A, Vuillier F, Scott-Algra D, Feuillie V, Dighiero G: Impaired proliferative capacity and abnormal cytokine profile of naive and memory CD4 T cells from HIV-seropositive patients. Clin Exp Immunol 1992, 88:478-483.
42. Aukrust P, Svardal AM, Müller F, Lunden B, Nordoy I, Froland SS: Markedly disturbed glutathione redox status in CD45RA+CD4+ lymphocytes in human immundeficiency virus type 1 infection is associated with selective depletion of this lymphocyte subset. Blood 1996, 88:2626-2633.
43. Garcia S, Dadaglio G, Cilote V, Chenal H, Bondurand A, Gougeon ML: Evidence for an in vivo superantigenic activity in human immunodeficiency virus-infected individuals. Blood 1996, 88:2151-2161.
44. Katzenstein TL, Gerstott J, Nielsen H: Assessments of plasma HIV RNA and CD4 cell counts after combined Pneumovax and tetanus toxoid vaccination: no detectable increase in HIV replication 6 weeks after immunization. Scand J Infect Dis 1996, 28:239-241.
45. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
46. Hammer SM: Advances in antiretroviral therapy and viral load monitoring. AIDS 1996, 10 (suppl 3):S1-S11.
47. Danner SA, Carr A, Leonard JM, et al.: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.